This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding the latest updates and clinical development trends in SCLC from ASCO 2024

Ticker(s): AMGN, ABBV, GSK, MRK

Who's the expert?

Institution: Mount Sinai

  • Assistant professor of Medicine, Hematology and Medical Oncology, and a board certified medical oncologist who specializes in the treatment of lung cancer and other thoracic malignancies.
  • Translational researcher focused on studying predictive biomarkers and developing novel targeted and immunotherapy trials aimed at improving treatment outcomes in lung cancer patients. 
  • PI of several lung cancer trials, including investigator initiated trials based on proteogenomic analyses used to identify novel therapeutic targets. 

Interview Goal
This interview will focus on the SCLC space presented at ASCO 2024 including the following:
  • Recent FDA approval of Amgen's Imdelltra (tarlatamab)
  • ADCs from AbbVie (ABBV-706) targeting SEZ6
  • ADCs from GSK/Hansoh (HS-20093) targeting B7-H3
  • HPN328 (DLL3 TCE) from Harpoon Therapeutic update
  • Results of Ph3 ADRIATIC study with Imfinzi in LS-SCLC

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.